Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
Stopped early · Early Phase 1 · Has a placebo group
Conditions studied: Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
In brief
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models. There are limited and contradictory clinical studies, however, and it is not clear if this peptide regulates blood pressure in humans. The purpose of this study is to better understand the cardiovascular effects angiotensin-(1-7) in human hypertension, and to examine interactions of this peptide with the autonomic nervous system. The investigators propose that the difficulties in showing angiotensin-(1-7) cardiovascular effects in previous clinical studies relates to the buffering capacity of the baroreceptor reflex to prevent changes in blood pressure. Autonomic failure provides the ideal patient population to test this hypothesis. These patients have loss of baroreflex buffering and have low levels of angiotensin-(1-7) in blood. The investigators will test if angiotensin-(1-7) infusion can lower blood pressure in patients with autonomic failure, and will determine the hemodynamic and hormonal mechanisms involved in this effect.
Key facts
- Study ID
- NCT02591173
- Run by
- Vanderbilt University Medical Center
- People needed
- 7
- Starts
- 2016-02-01
- Expected to finish
- 2020-07-01
- Last updated by the study team
- 2021-01-12
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Males and females of all races between 18 to 80 years of age.
- Diagnosed with primary autonomic failure and supine hypertension. Supine hypertension will be defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg while lying down.
- Able and willing to provide informed consent.
You may not qualify if…
- Pregnancy or breast feeding.
- Hemoglobin < 10.5 or hematocrit < 32.
- High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, renal failure, history of stroke or myocardial infarction).
- Inability to give or withdraw informed consent.
- Other factors which in the investigator's opinion would prevent the patient from completing the protocol (e.g. clinically significant abnormalities on clinical, mental examination, or laboratory testing or inability to comply with the protocol).
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.